Optimal confrontation of non-small cell lung cancer (NSCLC) remains a largely unachieved objective, as the 5-year survival rate struggles to surpass 15% ([@bib38]; [@bib40]). Most decisions throughout the clinical management of NSCLC are dictated by TNM staging. Surgical removal of tumours, where feasible, is the gold standard of treatment ([@bib37]; [@bib40]; [@bib45]; [@bib17]). However, even early-stage resected patients present an extremely variable oncologic outcome; this is a reflection of the large biological heterogeneity between patients who are currently erroneously categorised in the same prognostic group ([@bib38]). For example, adjuvant chemotherapy has not been proven to prolong the survival of stage I patients (especially stage IA; [@bib13]; [@bib40]; [@bib17]). Meanwhile, ∼30--40% of stage I NSCLC patients are expected to relapse within 5 years ([@bib30]; [@bib14]; [@bib59]), and this illustrates a severe inability, intrinsic to TNM staging, in defining high-risk patients who should receive adjuvant chemotherapy. In advanced disease stages, an accurate prognostic indicator could guide the administration of maintenance therapy, a clinical decision that currently remains under serious controversy ([@bib13]; [@bib37]; [@bib17]). Consequently, there is a necessity for novel molecular prognostic indicators that would enhance the conventional staging system and improve the decision-making process.

MicroRNAs (miRNAs) are regarded as a novel source of biomarkers for the majority of human malignancies ([@bib33]) and NSCLC is not an exception ([@bib44]). From the very first study, conducted in 2004 by Takamizawa *et al*, addressing the prognostic value of let-7 in NSCLC ([@bib43]), up to contemporary research, miRNAs are proving to have a decisive role in lung cancer pathobiology and to represent promising molecular markers for NSCLC prognosis ([@bib2]; [@bib42]; [@bib44]; [@bib26]).

MicroRNA 197 (miR-197) represents a molecule that is associated with a wide range of pathologic conditions ranging from non-neoplastic diseases (e.g., type 2 diabetes, myocardial infarction, metabolic syndrome) to major human malignancies (e.g., NSCLC, hepatocellular carcinoma, pancreatic cancer, thyroid cancer; detailed overview in [Table 1](#tbl1){ref-type="table"}). Interestingly, a recent study by [@bib12] provided strong evidence that miR-197 is a functional oncomiR with a central role in NSCLC pathogenesis, mediated through the suppression of the p53-dependent apoptotic cascade. MiR-197 targeting is therapeutically relevant, as it can inhibit tumour growth *in vivo* ([@bib12]). Previous studies had also shown that miR-197 regulates the expression of the tumour suppressor *FUS1* in NSCLC and is upregulated in the tissue and plasma of lung cancer patients ([@bib9]; [@bib56]).

Consequently, based on: (i) the robust association between miR-197 and NSCLC pathogenesis/progression ([@bib9]; [@bib12]), (ii) the key oncogenic role of miR-197 in aggressive human malignancies ([@bib15]; [@bib8]) and (iii) the diagnostic capacity of circulating miR-197 in lung cancer ([@bib56]; [@bib1]), we aimed to evaluate the previously unexplored potential of this lung oncomiR as a novel prognostic tissue biomarker for NSCLC.

Materials and methods
=====================

Collection, storage and characteristics of the NSCLC tissue specimens
---------------------------------------------------------------------

A total of 124 primary NSCLC tissue specimens, as well as 21 samples from normal tumour-adjacent tissue parts, were collected from surgically resected patients with early and advanced disease stages at the Trousseau Hospital, Tours, France, between 2006 and 2011. The mean age±s.e. of patients was 65.3±0.94. No neoadjuvant treatment was administered in these patients. All the participating patients gave their informed consent before the initiation of this study, which was designed and performed following the ethical guidelines of the Helsinki Declaration and the French bioethical committees.

Tissue samples were selected and reviewed by an experienced pathologist. The non-cancerous parts had a distance of at least 3 cm from the tumour. Upon selection, the samples were quickly frozen under liquid nitrogen and stored for further analysis at −80 °C. Histological diagnosis and tumour grading was established according to the World Health Organisation classification of lung tumours. Tumour staging was performed in agreement with the seventh lung cancer TNM classification and staging system. Detailed clinical and pathological characteristics of the patients collective are described in [Table 2](#tbl2){ref-type="table"}.

Tissue homogenisation, total RNA isolation, polyadenylation and reverse transcription
-------------------------------------------------------------------------------------

The Tissue-Tek O.C.T. (Sakura Finetek Europe, Alphen aan den Rijn, The Netherlands) and a cryotome (Thermo Scientific Inc., Waltham, MA, USA) platform were used for sectioning the fresh frozen NSCLC tissue samples (⩽50 mg tissue per sample). Consequently, the tissue parts were lysed in 430 *μ*l lysis buffer (RLT Plus, Qiagen Inc., Valencia, CA, USA) with 143 *μ*M *β*-mercaptoethanol and, upon complete homogenisation, were centrifuged for 1 min at maximum speed. Total RNA was isolated from the resulting supernatant using QIAsymphony SP workstation and the RNA CT 400 protocol (Qiagen Inc.). To avoid DNA contamination, digestion with DNAse I was also performed. The quantity, quality and purity of the resulting RNA were thoroughly assessed by a NanoDrop 2000c spectrophotometer (Thermo Scientific Inc.) and an Agilent 2100 bioanalyzer. Only intact RNA samples with RIN\>6 were considered for downstream applications.

Polyadenylation and reverse transcription of total RNA, including miRNAs, was performed as previously described ([@bib31]). In brief, 500 ng of RNA was polyadenylated in the presence of ATP (800 *μ*[M]{.smallcaps}) by 1 U of *E. coli* Poly(A) Polymerase in the reaction buffer supplied by the manufacturer (New England Biolabs Inc., Ipswich, MA, USA) at 37 °C for 60 min, followed by an enzyme inactivation step at 65 °C for 10 min. Immediately after that, the polyadenylated RNA was reverse transcribed into first-strand cDNA in a 20 *μ*l reaction containing the reaction buffer of the manufacturer, 100 U M-MLV reverse transcriptase in the reaction, 20 U RNaseOUT recombinant ribonuclease inhibitor (Invitrogen, Carlsbad, CA, USA) and 0.25 *μ*[M]{.smallcaps} poly(T) adapter (5′-GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN-3′) at 37 °C for 60 min, followed by an enzyme inactivation step at 70 °C for 15 min.

Quantitative PCR for miR-197 expression analysis
------------------------------------------------

MiR-197-3p expression levels were quantified using a SYBR-Green-based qPCR assay in a 10-*μ*l reaction, which was run in duplicates in 96-well fast reaction plates (Applied Biosystems, Carlsbad, CA, USA). The reactions consisted of Kapa SYBR Fast Universal qPCR Master Mix (Kapa Biosystems, Wilmington, MA, USA) including Rox Low passive reference dye, a specific miR-197-3p- (5′-CACCACCTTCTCCACCCA-3′) or a SNORD48- (5′-TGATGATGACCCCAGGTAACTCT-3′) specific forward primer and a universal reverse primer (5′-GCGAGCACAGAATTAATACGAC-3′), all at a final concentration of 200 n[M]{.smallcaps}, as well as 1 ng of cDNA as template. The sizes of the miR-197 and SNORD48 amplicons were 62 and 105 bp, respectively. The qPCR reactions took place in a 7500 Fast Real-Time PCR System (Applied Biosystems) using the following rapid cycling thermal protocol: a 3-min polymerase activation step at 95 °C and 40 cycles of denaturation --- annealing/extension steps at 95 °C for 3 s --- 60 °C for 30 s. The melting curve analysis protocol followed immediately after. Each run included a no-template control. MiR-197 expression levels were normalised to the endogenous reference control SNORD48 using the formula Δ*C*~T~=*C*~T~^miR-197^−*C*~T~^SNORD48^. To allow inter-run comparisons, the same designated cancerous sample (calibrator) was included in all qPCR runs. MiR-197 relative quantification (RQ) expression units were calculated relatively to the calibrator via the formula RQ=2^−ΔΔ*C*T^, where ΔΔ*C*~T~=Δ*C*~T~^sample^−Δ*C*~T~^calibrator^, by the 7500 software v.2.06 (Applied Biosystems).

Quality control of the developed qPCR method
--------------------------------------------

The developed qPCR method went through quality control to verify its specificity, sensitivity and reproducibility. To test the specificity of the reactions, melting curve analysis and agarose gel electrophoresis were performed ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). The presence of a unique peak in the melting curve and a unique band detected after 3.0% agarose gel electrophoreses corroborated that a single specific amplicon was produced for each case throughout the qPCR reactions.

We also assayed a series of negative control samples, including no-template controls, enzyme-negative controls (reverse transcriptase, poly(A)polymerase), as well as DNA template controls, all of which failed to generate a detectable *C*~T~ value.

Standard curves were performed for both the endogenous and target molecules, by using a series of cDNA dilutions covering 5 orders of magnitude (*r*^*2*^=0.999 for SNORD48 and *r*^*2*^=0.998 for miR-197). PCR efficiencies were calculated using the slopes of the standard curves equal to 95% for SNORD48 and 100% for miR-197 ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}); the presence of similar qPCR efficiencies that are both under the acceptable range allows the use of the comparative C~T~ method and excludes any PCR inhibition.

The method\'s reproducibility was assessed by analysing common samples (*n*=7) in different qPCR runs and calculating the coefficient of variation from duplicate measurements ([@bib18]). The inter-assay CV was found to be 7.8%.

Biostatistical analyses -- internal validation
----------------------------------------------

Spearman\'s correlation analysis was used to analyse the associations between the continuous variables of the study. The analysis of differences in miR-197 expression levels between distinct groups of NSCLC patients was performed via the Mann--Whitney *U*-test or the Jonckheere--Terpstra test, where applicable. Paired samples analysis was conducted according to Wilcoxon signed-rank test.

The X-tile algorithm ([@bib4]) was used to classify patients into miR-197-high- and miR-197-low-expression groups. More precisely, X-tile was utilised to select an optimal cutoff point while correcting for the use of minimum *P*-value statistics. Two robust methods of *P*-value correction were used that produced a cutoff with minimal chance of type I errors: (i) the Miller--Siegmund *P*-value correction and (ii) the Monte-Carlo simulations by cross-validation and the corrected *P*-value approaches based on 1000 random populations. Internal validation was also performed by using the X-tile option for automatically generating random training and validation cohorts, finding the optimal cutoff point in the training set and applying this cutoff to the validation cohort; a similar procedure was also followed by creating random training and validation sets via the SPSS software. All the aforementioned methods produced the same optimal cutoff point, that is, 0.635 RQ units of miR-197 expression (61st percentile).

After establishing and internally validating the robustness of the selected cutoff, survival analysis was performed by generating the Kaplan--Meier overall survival (OS) curves to evaluate the prognostic potential of miR-197 expression for NSCLC patients. Cox regression models were developed at the univariate and multivariate levels. Multivariate Cox regression was performed with the purpose of testing for independence of the miR-197-driven prognostic information, adjusting for potentially confounding variables via a standardised and a final model. The standardised model included the marker under evaluation (miR-197) along with standard prognostic variables (tumour size, nodal status, pTNM stage, differentiation, histotype), as well as typical patient demographic variables (age and gender); this standardised model can facilitate the comparison of the prognostic performance of miR-197 across the present and future studies. The final multivariate model included the variables that were found to be robustly associated with OS in univariate analysis at a statistically significant level (i.e., miR-197, pTNM stage and differentiation status). The robustness of all the above-mentioned models was validated by the bootstrap approach. Random sampling was performed with replacement, producing 1000 bootstrap samples; the bias corrected and accelerated approach was followed for the calculation of 95% confidence interval (CI).

We then followed a complementary statistical approach, based on the stratification of patients into subgroups, and the application of the Kaplan--Meier survival analyses for miR-197 expression in these groups. This approach was followed to evaluate the prognostic performance of miR-197 in meaningful subgroups of patients and irrespective of different treatments.

All the aforementioned statistical analyses were performed using the X-tile v3.6.1 (Yale University, New Haven, CT, USA), SPSS Statistics v20.0 (IBM Corp., Armonk, NY, USA) and MedCalc v.12.5 (MedCalc Software, Ostend, Belgium) software. Two-tailed tests were used and *P*-values \<0.05 were adapted for statistical significance.

Results
=======

The expression of miR-197 in NSCLC tissues is associated with larger tumour size, and squamous cell carcinoma tumours
---------------------------------------------------------------------------------------------------------------------

By analysing 21 cancerous and tumour-adjacent normal tissue pairs, no statistically significant difference was observed regarding miR-197 expression (*P*=0.357). The expression levels of miR-197 in the 124 NSCLC tissue samples analysed ranged from 0.159 to 2.46 RQ units, with a median value of 0.512 and a mean±s.e.=0.618±0.035.

The expression of miR-197 in cancer was positively associated with tumour size, as it was increased in patients harbouring tumours \>3 cm compared with patients with ⩽3 cm tumours (*P*=0.042). MiR-197 levels were also elevated in squamous cell carcinoma compared with adenocarcinoma (*P*=0.032; [Figure 1](#fig1){ref-type="fig"}). A weak, positive correlation was also observed between the expression levels of miR-197 and patients\' age (*r*~s~=0.178, *P*=0.048), whereas no significant associations were observed between miR-197 expression and pTNM stage (*P*=0.496), tumour differentiation (*P*=0.141), lymph node status (*P*=0.951), metastasis (*P*=0.910), smoking status (*P*=0.371), pack-years (*P*=0.826), the presence of chronic obstructive pulmonary disease (*P*=0.589) or gender (*P*=0.093).

Stratification to high- and low-risk groups based on miR-197 expression: selection of an optimal cutoff value and internal validation
-------------------------------------------------------------------------------------------------------------------------------------

An appropriate cutoff (equal to 0.635 RQ units) that was able to effectively stratify our cohort, with respect to OS probabilities, was selected while correcting the chance of type I errors (Miller--Siegmund *P*=0.022). Monte-Carlo simulations in 1000 random populations resulted in the same, statistically significant results (cross--validation *P*=0.027, Monte-Carlo corrected *P*=0.031). The aforementioned cutoff value was identified in the X-tile randomly generated training cohort as optimal (*P*=0.034) and then its validity was confirmed in the validation cohort (*P*=0.012). The same results were obtained by creating random training and validation cohorts via SPSS (optimal cutoff=0.635, *P*=0.030 for the training and *P*=0.004 for the validation cohort, according to the Kaplan--Meier analysis).

MiR-197 is robustly associated with adverse oncologic outcome
-------------------------------------------------------------

Complete follow-up data regarding the OS of NSCLC patients were available for the whole cohort (*n*=124). Median follow-up time was 27.5 months (1.0--81 months); median follow-up in patients still alive at the time of analysis was 40 months (14--81 months).

As indicated by the Kaplan--Meier survival analysis, patients categorised as miR-197-high clearly presented (*P*=0.0007) a worse OS course compared with the miR-197-low ones ([Figure 2A](#fig2){ref-type="fig"}). The median survival time for miR-197-low individuals was 61 months, which is in striking difference with the corresponding period of 23 months for miR-197-high patients. Furthermore, when focusing on the 1-year survival time point, it was demonstrated that miR-197 levels were considerably higher among the deceased patients (median=0.740 RQ units) by 1 year compared with the survivors (median=0.490 RQ units) at 1 year (*P*=0.017; [Figure 2B](#fig2){ref-type="fig"}).

The above-mentioned prognostic potential of miR-197 was corroborated (*P*=0.001) by univariate Cox proportional hazard regression analysis with bootstrap resampling. Patients stratified as miR-197-high were 2.31 times more likely (95% CI=1.44--3.73) to die compared with miR-197-low ones. As expected, advanced pTNM stage (HR=1.89, 95% CI=1.21--3.23, *P*=0.011), and poor tumour differentiation (HR=2.12, 95% CI=1.24--3.84, *P*=0.006), also emerged as significant indicators of adverse oncologic outcome ([Table 3](#tbl3){ref-type="table"}).

MiR-197: a novel independent predictor of unfavourable prognosis for NSCLC patients
-----------------------------------------------------------------------------------

By using multivariate Cox regression analysis, adjusted for standard prognostic indicators and typical demographic factors, it was demonstrated that miR-197 expression is a strong and independent predictor (*P*=0.007) of adverse oncologic outcome (HR=2.52, 95% CI=1.23--6.21) for NSCLC patients ([Table 3](#tbl3){ref-type="table"}). Other important predictors were pTNM stage (HR=2.83, 95% CI=1.08--8.69, P=0.014) and differentiation status (HR=2.20, 95% CI=1.09--5.52, P=0.023; [Table 3](#tbl3){ref-type="table"}).

All statistically significant predictors (miR-197, tumour stage and differentiation) were included in a final model, in which only miR-197 retained its robust prognostic performance (HR=1.97, 95% CI=1.10--3.38, *P*=0.013; [Table 3](#tbl3){ref-type="table"}).

Tissue miR-197 expression is associated with unfavourable prognosis in subgroups of NSCLC patients
--------------------------------------------------------------------------------------------------

As demonstrated in [Figure 3](#fig3){ref-type="fig"}, miR-197 expression is significantly associated with adverse oncologic outcome in both stage I (*P*=0.045) and more advanced stages (II--IV; *P*=0.036; [Figure 3A and B](#fig3){ref-type="fig"}, respectively). These results were confirmed by univariate Cox regression, which showed that stage I patients with high miR-197 expression presented a poorer OS course compared with patients categorised as miR-197-low (HR=2.34, 95% CI=0.974--5.64, *P*=0.044). For stage II--IV patients, the corresponding HR value was 1.93 (95% CI=1.06--3.90, *P*=0.038).

In addition, miR-197 showed a statistically significant ability for risk stratification of NSCLC patients regarding OS, irrespectively of the administration of post-operative chemotherapy (*P*=0.042), [Figure 3C](#fig3){ref-type="fig"} and HR=1.95, 95% CI=0.99--4.15, *P*=0.048) or not (*P*=0.045, [Figure 3D](#fig3){ref-type="fig"} and HR=2.23, 95% CI=0.935--5.47, *P*=0.045).

Discussion
==========

Contemporary research has proven that molecular signatures can constitute the first, yet decisive, step towards the realisation of personalised cancer care. Successful examples include the routinely used gene expression tests MammaPrint and OncotypeDx for breast cancer ([@bib10]) and the recently FDA-approved multifactorial biomarker panels ROMA score and OVA1 for ovarian cancer ([@bib24]). Novel molecular prognostic indicators, such as miRNAs, could also aid towards enhancing the clinical management of NSCLC patients ([@bib27]; [@bib38]). The advantage of miRNAs as prognostic biomarkers include: (i) their reliable and cost-efficient quantification in specimens accompanied by invaluable clinical information such as FFPE tissues, as well as in minimal diagnostic tissue specimens from biopsies ([@bib2]; [@bib42]; [@bib26]), (ii) the enhanced clinical information regarding molecular cancer pathogenesis that can derive from their expression analysis; an alteration in the expression of a single miRNA molecule usually reflects changes affecting a broad range of biological pathways ([@bib2]; [@bib33]). MiRNAs are currently investigated as biomarkers for several human malignancies, including NSCLC, in \>100 clinical trials ([@bib33]).

In the present study we show that miR-197 is robustly associated with an adverse OS outcome in NSCLC patients, independently of several important prognostic indicators such as pTNM stage ([Table 3](#tbl3){ref-type="table"}). After analysing meaningful NSCLC patient subgroups, we demonstrate that miR-197 retains its predictive properties in stage I, as well as in more advanced disease stages ([Figure 3](#fig3){ref-type="fig"}). Interestingly, miR-197 has already been evaluated as a circulating diagnostic marker for NSCLC; plasma and serum measurements of miR-197 can distinguish lung cancer patients from healthy individuals ([@bib56]; [@bib1]) and when they are used in combination with other miRNA molecules are predictive of lung cancer risk and the presence of aggressive disease ([@bib3]) ([Table 1](#tbl1){ref-type="table"}).

The apparent association between tissue miR-197 expression and adverse oncologic outcome, described in the present study, is in fine agreement with its previously reported oncogenic role in lung cancer ([@bib9]; [@bib12]). More precisely, it has been recently proven that miR-197 exerts its lung tumour-promoting role by inhibiting the p53 apoptotic cascade, through a mechanism that includes the suppression of *NOXA* and *BMF* genes; interestingly, *in vivo* experiments showed that miR-197 inhibition suppresses tumour growth and has therapeutic relevance for NSCLC ([@bib12]). A previous study had also shown that miR-197 targets the tumour suppressor *FUS1* ([@bib9]). In addition, [@bib51] reported, based on microarray data, that miR-197 is upregulated in cancerous versus non-cancerous lung tissues. In our study, we did not observe such an upregulation; this might be attributed to the limited sample size of non-cancerous tissues that we had available and/or the different techniques for miR-197 determination that were used between the two studies. However, we found that tissue miR-197 expression was associated with the presence of larger tumours (*P*=0.042) and the squamous cell carcinoma histotype (*P*=0.032). MiR-197 has also been described as oncogenic in a series of other aggressive malignancies. In hepatocellular carcinoma, miR-197 is upregulated and linked with enhanced cell migration, invasion and metastasis both *in vitro* and *in vivo* ([@bib8]). In pancreatic cancer, miR-197 is upregulated and has been shown to promote cell migration, invasion, epithelial--mesenchymal transition and metastasis ([@bib15]). In thyroid cancer, the observed upregulation of miR-197 has been associated with carcinogenesis ([@bib49]).

Despite following the internal validation and quality control procedures, the results of our study still require rigorous external validation though independent, larger and ideally multicentric cohorts, to comprehensively corroborate the prognostic significance of miR-197. Given the previously reported biological link between miR-197 and p53, it would be interesting to investigate if the prognostic performance of miR-197 can be improved by including the p53 mutation status of NSCLC patients. Considering that the qPCR technique that we used cannot account for tissue heterogeneity, it would be fitting to analyse, in a future study, the expression of miR-197 through *in situ* hybridisation to evaluate if there is any association between miR-197 staining intensity in distinct tissue parts and tumour aggressiveness and/or oncologic outcome. Another interesting perspective would be the clinical evaluation of tissue or circulating miR-197 levels as a biomarker for predicting or monitoring chemotherapy response in NSCLC.

According to our data, the cost-effective expression analysis of miR-197 at the time of diagnosis could be considered further as a novel molecular tool that could contribute to a more optimised clinical management for NSCLC patients.
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![**Distribution of miR-197 expression in NSCLC tissues.** Distribution of miR-197 expression in NSCLC tissues of different tumour size (**A**) and histotype (**B**). ADC=adenocarcinoma, SCC=squamous cell carcinoma. *P*-value calculated by the Mann--Whitney *U*-test. *y* axis is in logarithmic scale. Bold lines represent the median value.](bjc2015119f1){#fig1}

![**Association of miR-197 expression with unfavourable prognosis in the whole cohort of NSCLC patients.** (**A**) Kaplan--Meier OS curves for the whole cohort of NSCLC patients, classified as miR-197-high and miR-197-low. *P*-value calculated by the log-rank test. (**B**) MiR-197 expression levels in NSCLC patients deceased by 1 year and alive at 1 year post surgery. *P*-value calculated by the Mann--Whitney *U*-test. Bold lines represent the median value. \*Outliers.](bjc2015119f2){#fig2}

![**Kaplan--Meier survival analyses for NSCLC patient subgroups.** Stage I (**A**), advanced stages II--IV (**B**), adjuvant chemotherapy treated (**C**), no adjuvant chemotherapy treated (**D**) patients. *P*-values calculated by the log-rank test.](bjc2015119f3){#fig3}

###### The role of miR-197 in malignant and non-malignant diseases

  **Disease**                        **Description**                                                                                                                                                                                                                                                                                                                                              **References**
  ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------
  **Human Malignancies**                                                                                                                                                                                                                                                                                                                                                                          
  Lung cancer                        Oncogenic activity, through the suppression of p53-dependent apoptotic cascade, including repression of *NOXA* and *BMF* genes                                                                                                                                                                                                                               [@bib12]
                                     Upregulated in lung cancer compared with non-cancerous tissues                                                                                                                                                                                                                                                                                               [@bib51]
                                     Upregulated in the plasma of lung cancer patients compared with controls, including stage I patients compared with controls. Upregulated in the plasma of lung cancer patients with metastasis compared with metastasis-free patients. Decreased plasma levels in patients that respond to chemotherapy (*n*=14)                                             [@bib56]
                                     Upregulated in the serum of lung cancer patients compared with controls. Downregulated in the serum of lung cancer patients with metastasis compared with metastasis-free patients                                                                                                                                                                           [@bib1]
                                     Regulator of the tumour suppressor *FUS1* in lung cancer. Elevated miR-197 expression is correlated with reduced Fus1 expression in NSCLC tumour specimens                                                                                                                                                                                                   [@bib9]
                                     Serum miR-197 measurements in combination with other miRNAs are associated with risk of lung cancer development and can predict the presence of aggressive disease (e.g., miR-197/miR-451, miR-197/miR-660, miR-197/miR-486-5p)                                                                                                                              [@bib3]
  Hepatocellular carcinoma           Upregulated in hepatocellular carcinoma (HCC) tissues compared with normal hepatic tissues. Downregulation of miR-197 coupled with the upregulation of the tumour metastasis suppressor CD82 in HCC cells leads to the inhibition of HCC migration and invasion *in vitro* and *in vivo*. Anti-miR-197 repressed lung cancer metastatic nodes in nude mice   [@bib8]
  Pancreatic cancer                  Upregulated in invasive ductal adenocarcinoma tissues compared with normal pancreas and intraductal papillary mucinous adenoma. Enhances cellular migration and invasion of pancreatic cancer cells and promotes EMT and metastasis by targeting p120 catenin                                                                                                [@bib15]
                                     Upregulated in pancreatic cancerous compared with normal tissue parts                                                                                                                                                                                                                                                                                        [@bib46]
  Thyroid cancer                     Upregulated in tissue samples of oncocytic follicular carcinomas compared with normal thyroid tissue. Upregulated in thyroid tumours compared with hyperplastic nodules                                                                                                                                                                                      [@bib34]
                                     Upregulated in tissue samples of follicular thyroid carcinoma (FTC) compared with follicular adenoma. Contribution to FTC carcinogenesis. Inhibition of miR-197 in thyroid cancer cells induces growth arrest                                                                                                                                                [@bib49]
                                     Expression of miR-197 along with other miRNAs combined in a predictive model can differentiate malignant from benign indeterminate thyroid lesions                                                                                                                                                                                                           [@bib20]
  Ovarian cancer                     Upregulated in recurrent compared with primary ovarian cancer                                                                                                                                                                                                                                                                                                [@bib21]
  Cervical carcinoma                 Upregulated in cervical carcinoma tissues compared with atypical dysplasia                                                                                                                                                                                                                                                                                   [@bib36]
  Tongue SCC                         Upregulated in cancerous compared with paired normal tissue parts                                                                                                                                                                                                                                                                                            [@bib50]
  Prostate cancer                    Upregulated in prostate cancerous compared with normal tissues                                                                                                                                                                                                                                                                                               [@bib46]
  Breast cancer (male)               Upregulated in male breast cancer tissues compared with gynaecomastia specimens                                                                                                                                                                                                                                                                              [@bib22]
  Oral cancer                        Downregulation of miR-197 (tissue and saliva) levels in progressing low-grade dysplasia leukoplakia                                                                                                                                                                                                                                                          [@bib53]
  Gastric cancer                     Downregulated in gastric cancerous compared with paired normal tissue                                                                                                                                                                                                                                                                                        [@bib25]
  Colon cancer                       Downregulation in colon cancer cells *in vitro* upon administration of chemotherapeutics                                                                                                                                                                                                                                                                     [@bib58]
  Breast cancer                      Downregulated upon progestins administration                                                                                                                                                                                                                                                                                                                 [@bib41]
  Malignant astrocytomas             Serum levels decreased in patients with malignant astrocytomas compared with normal controls and with astrogliosis samples                                                                                                                                                                                                                                   [@bib52]
  Anaplastic large-cell lymphoma     Upregulation that differentiates anaplastic lymphoma kinase-negative (−) anaplastic large-cell lymphomas from other peripheral T-cell lymphomas                                                                                                                                                                                                              [@bib28]
  Osteosarcoma                       Downregulated in Apurinic/apyrimidinic endonuclease1-knockdown osteosarcoma cells                                                                                                                                                                                                                                                                            [@bib7]
  **Non-malignant diseases**                                                                                                                                                                                                                                                                                                                                                                      
  Pneumonia                          Upregulated in serum of patients with pneumonia compared with controls                                                                                                                                                                                                                                                                                       [@bib1]
  Tuberculosis                       Upregulated in serum of patients with pulmonary tuberculosis compared with controls                                                                                                                                                                                                                                                                          [@bib1]
  Uterine leiomyomas                 Downregulated in human uterine leiomyomas compared with matched myometrium                                                                                                                                                                                                                                                                                   [@bib48]
  Type 2 diabetes                    Downregulated in the plasma of prevalent type 2 diabetes patients compared with control samples                                                                                                                                                                                                                                                              [@bib54]
  Myocardial infarction              Serum miR-197 levels are inversely associated with disease risk                                                                                                                                                                                                                                                                                              [@bib55]
  Metabolic syndrome                 Expression in exosomes is associated with dyslipidemia in metabolic syndrome                                                                                                                                                                                                                                                                                 [@bib19]
                                     MiR-197 measured in serum is associated with decreased metabolic syndrome risk                                                                                                                                                                                                                                                                               [@bib57]
  Multiple sclerosis                 Downregulation in peripheral blood T cells from MS patients compared with controls                                                                                                                                                                                                                                                                           [@bib16]
  Alzheimer\'s disease               Upregulated in Alzheimer disease brain parenchyma, and cerebrospinal fluid                                                                                                                                                                                                                                                                                   [@bib29]
  Neural tube defects (NTDs)         An SNP (rs7646) affecting miR-197 binding affinity to the MTHFD1L (methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like) 3′ UTR is associated with increased risk of NTDs                                                                                                                                                                        [@bib32]
  Steatohepatitis                    miR-197 measured in adipose tissue is associated with pericellular fibrosis in NASH patients                                                                                                                                                                                                                                                                 [@bib11]
  Preeclampsia                       Upregulated in placenta tissues from patients with preeclampsia compared with normotensive placenta                                                                                                                                                                                                                                                          [@bib6]
  Varicella-zoster virus infection   Upregulated in the serum of varicella patients from healthy controls and other microbial infections                                                                                                                                                                                                                                                          [@bib39]
  Hepatitis B virus infection        Downregulated gradually in peripheral blood mononuclear cells of hepatitis B-infected patietns with disease symptoms deterioration; possibly targets IL-18                                                                                                                                                                                                   [@bib5]
  Biliary cirrhosis                  Decreased circulating levels in primary biliary cirrhosis compared with healthy controls and hepatitis                                                                                                                                                                                                                                                       [@bib35]
  Psoriasis                          Downregulated in psoriatic compared with normal skin tissues and psoriatic uninvolved skin tissue parts                                                                                                                                                                                                                                                      [@bib23]
  Melanocyte dysfunction disease     Upregulated in microphthalmia-associated transcription factor knocked down melanocytes                                                                                                                                                                                                                                                                       [@bib47]

Abbreviations: EMT=epithelial--mesenchymal transition; IL-18=interleukin-18; miRNA=microRNA; MS, multiple sclerosis; NSCLC=non-small cell lung cancer; SCC=squamous cell carcinoma; SNP=single-nucleotide polymorphism.

###### Clinicopathological and demographic characteristics of the NSCLC patients

  **Variable**                      ***N*** **(%)**
  -------------------------------- -----------------
  **Gender**                       
  Male                                100 (80.6)
  Female                               24 (19.4)
  **Smoking status**               
  Non-smoker                           12 (9.8)
  Smoker                              111 (90.2)
  x                                        1
  **Pack-years**                   
  \<21                                 14 (12.8)
  21--49                               59 (54.1)
  \>49                                 36 (33.0)
  x                                       15
  **Histotype**                    
  Squamous cell carcinoma              51 (41.1)
  Adenocarcinoma                       67 (54.0)
  Other                                 6 (4.8)
  **COPD**                         
  No                                   61 (50.0)
  Yes                                  61 (50.0)
  x                                        2
  **Differentiation**              
  Poorly differentiated                34 (27.9)
  Moderately/well differentiated       88 (72.1)
  x                                        2
  **Tumour size**                  
  ⩽3 cm                                36 (29.0)
  \>3 cm                               88 (71.0)
  **Lymph node**                   
  Negative                             70 (56.9)
  Positive                             53 (43.1)
  x                                        1
  **Metastasis**                   
  Negative                            106 (85.5)
  Positive                             18 (14.5)
  **pTNM stage**                   
  IA                                   21 (17.1)
  IB                                   34 (27.6)
  IIA                                  10 (8.1)
  IIB                                  12 (9.8)
  IIIA                                 23 (18.7)
  IIIB                                  5 (4.1)
  IV                                   18 (14.6)
  x                                        1
  **Deceased**                     
  No                                   63 (50.8)
  Yes                                  61 (49.2)
  **Adjuvant chemotherapy**        
  No                                   65 (52.8)
  Yes                                  58 (47.2)
  x                                        1

Abbreviations: COPD=chronic obstructive pulmonary disease; NSCLC=non-small cell lung cancer; pTNM=postsurgical pathologic tumour node metastasis; x=unknown.

###### Univariate and multivariate Cox logistic regression analyses for the prediction of NSCLC patients\' OS course

  **Variable**           **HR**   **95% CI**[a](#t3-fn2){ref-type="fn"}   ***P*****-value**                **HR**                **95% CI**[a](#t3-fn2){ref-type="fn"}           ***P*****-value**
  --------------------- -------- --------------------------------------- ------------------- ---------------------------------- ---------------------------------------- ----------------------------------
  **miR-197**                                                                                                                                                            
  Low                     1.00                                                                              1.00                                                                          
  High                    2.31                 1.44--3.73                       0.001         2.52[b](#t3-fn3){ref-type="fn"}    1.23--6.21[b](#t3-fn3){ref-type="fn"}    0.007[b](#t3-fn3){ref-type="fn"}
                                                                                              1.97[c](#t3-fn4){ref-type="fn"}    1.10--3.38[c](#t3-fn4){ref-type="fn"}    0.013[c](#t3-fn4){ref-type="fn"}
  **Tumour size**                                                                                                                                                        
  ⩽3 cm                   1.00                                                                              1.00                                                                          
  \>3 cm                  1.79                 0.963--3.89                      0.069         1.98[b](#t3-fn3){ref-type="fn"}    0.905--5.93[b](#t3-fn3){ref-type="fn"}   0.086[b](#t3-fn3){ref-type="fn"}
  **Nodal status**                                                                                                                                                       
  Lymph node negative     1.00                                                                              1.00                                                                          
  Lymph node positive     1.51                 0.922--2.62                      0.100         0.475[b](#t3-fn3){ref-type="fn"}   0.162--1.43[b](#t3-fn3){ref-type="fn"}   0.096[b](#t3-fn3){ref-type="fn"}
  **pTNM stage**                                                                                                                                                         
  I                       1.00                                                                              1.00                                                                          
  II--IV                  1.89                 1.21--3.23                       0.011         2.83[b](#t3-fn3){ref-type="fn"}    1.08--8.69[b](#t3-fn3){ref-type="fn"}    0.014[b](#t3-fn3){ref-type="fn"}
                                                                                              1.73[c](#t3-fn4){ref-type="fn"}    0.978--3.36[c](#t3-fn4){ref-type="fn"}   0.065[c](#t3-fn4){ref-type="fn"}
  **Differentiation**                                                                                                                                                    
  Moderately/well         1.00                                                                                                                                                            
  Poor                    2.12                 1.24--3.85                       0.006         2.20[b](#t3-fn3){ref-type="fn"}    1.09--5.52[b](#t3-fn3){ref-type="fn"}    0.023[b](#t3-fn3){ref-type="fn"}
                                                                                              1.74[c](#t3-fn4){ref-type="fn"}    0.942--3.55[c](#t3-fn4){ref-type="fn"}   0.054[c](#t3-fn4){ref-type="fn"}
  **Histotype**                                                                                                                                                          
  SCC                     1.00                                                                                                                                                            
  ADC                     1.11                 0.654--1.97                      0.674         1.19[b](#t3-fn3){ref-type="fn"}    0.593--2.46[b](#t3-fn3){ref-type="fn"}   0.578[b](#t3-fn3){ref-type="fn"}
  Age (continuous)       0.989                 0.967--1.01                      0.352         0.977[b](#t3-fn3){ref-type="fn"}   0.951--1.01[b](#t3-fn3){ref-type="fn"}   0.077[b](#t3-fn3){ref-type="fn"}
  **Gender**                                                                                                                                                             
  Male                    1.00                                                                                                                                                            
  Female                 0.844                 0.443--1.56                      0.579         1.102[b](#t3-fn3){ref-type="fn"}   0.445--3.13[b](#t3-fn3){ref-type="fn"}   0.798[b](#t3-fn3){ref-type="fn"}

Abbreviations: ADC=adenocarcinoma; CI=confidence interval; HR=hazards ratio; NSCLC=non-small cell lung cancer; OS=overall survival; pTNM=postsurgical pathologic tumour node metastasis; SCC=squamous cell carcinoma.

On the basis of 1000 bootstrap samples and following the Bias corrected and accelerated (BCa) approach.

Standardised model: includes all variables reported in the univariate analysis.

Final model: includes miR-197, pTNM stage and differentiation status.
